BiotechTube
Kedrion Biopharma

Kedrion Biopharma

Fort Lee, United States· Est.
kedrion.us
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

Kedrion Biopharma is a significant global player in the plasma-derived therapeutics sector, operating a network of plasma collection centers and fractionation facilities. The company's product portfolio includes immunoglobulins, albumin, clotting factors, and hyperimmune globulins, which are critical for patients with rare and chronic conditions. As a private company, it competes in a consolidated market dominated by a few large firms, leveraging its integrated supply chain from plasma collection to final product distribution. Its strategic focus is on expanding its geographic footprint and product pipeline to address growing global demand for plasma therapies.

Rare DiseasesImmunologyHematologyNeurologyInfectious Diseases

Technology Platform

Industrial-scale plasma fractionation using cold ethanol separation, chromatographic purification, and viral inactivation/removal processes for producing plasma-derived therapies.

Funding History

1
Total raised:$200M
Debt$200M

Opportunities

Growing global demand for plasma-derived therapies, especially immunoglobulins, driven by new indications and increased diagnosis in emerging markets.
The critical need for plasma supply creates a high barrier to entry, favoring integrated players like Kedrion.
Expansion of subcutaneous formulations and hyperimmune globulins for pandemic preparedness offer avenues for portfolio diversification and higher-margin products.

Risk Factors

Heavy reliance on a voluntary and costly plasma supply chain, which is vulnerable to economic and social disruptions.
Intense competition from larger, better-capitalized public companies (CSL, Takeda, Grifols).
Significant regulatory and safety risks associated with manufacturing biologics from human blood, where any contamination event could have severe consequences.

Competitive Landscape

Kedrion operates in a highly consolidated global market dominated by four major players: CSL Behring, Takeda (Baxalta/Shire), Grifols, and Octapharma. These competitors have larger scale, broader product portfolios, and greater financial resources. Kedrion's position as a mid-sized, private, integrated fractionator allows for agility but requires strategic focus on operational efficiency and niche markets to compete effectively.

More companies in Biologics / Biosimilars →More companies in United States →